1. Search Result
Search Result
Results for "

Target ability

" in MedChemExpress (MCE) Product Catalog:

152

Inhibitors & Agonists

8

Screening Libraries

53

Biochemical Assay Reagents

14

Peptides

5

Inhibitory Antibodies

5

Natural
Products

1

Isotope-Labeled Compounds

8

Click Chemistry

13

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100474
    SKQ1
    Maximum Cited Publications
    20 Publications Verification

    Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    SKQ1 is a mitochondrial-targeted antioxidant with the high mitochondrion membrane penetrating ability and potent antioxidant capability .
    SKQ1
  • HY-125399
    PSMA-11
    1 Publications Verification

    HBED-CC-PSMA

    PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .
    PSMA-11
  • HY-113011
    Maltotriose
    1 Publications Verification

    Endogenous Metabolite Others
    Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer .
    Maltotriose
  • HY-P11069

    Biochemical Assay Reagents Metabolic Disease
    Kidney-targeting peptide is a kidney-targeting peptide (KTP). Kidney-targeting peptide significantly enhances the renal targeting ability of Isoquercitrin (HY-N1445). Kidney-targeting peptide can be used in diabetic nephropathy research .
    Kidney-targeting peptide
  • HY-W243303J

    Biochemical Assay Reagents Cancer
    Poly(acrylic acid) (MW 250000) is a synthetic cationic electrolyte containing abundant carboxyl groups (-COOH), which exhibits excellent water absorption and retention properties and is often cross-linked to form hydrogels. Poly(acrylic acid) (with a molecular weight of 250,000). Poly(acrylic acid) (MW 250000) can be used as a non-collagenous analog in the biomimetic mineralization research of type I collagen. Poly(acrylic acid) (MW 250000) has pH responsiveness and biocompatibility and is often used as a drug carrier, surface modifier and functional material .
    Poly(acrylic acid) (MW 250000)
  • HY-122909
    GSK2593074A
    1 Publications Verification

    GSK'074

    RIP kinase Inflammation/Immunology
    GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3 .
    GSK2593074A
  • HY-104013
    Aminopurvalanol A
    1 Publications Verification

    CDK Apoptosis Cancer
    Aminopurvalanol A is a potent, selective, and cell permeable inhibitor of Cyclins/Cdk complexes. Aminopurvalanol A preferentially targets the G2/M-phase transition inhibiting cancer cell differentiation. Aminopurvalanol A causes the inhibition of sperm fertilizing ability via the inhibition of physiological capacitation-dependent actin polymerization .
    Aminopurvalanol A
  • HY-D1005A23

    PEG-PPG-PEG, 4400 (Average)

    Environmental Pollutants Biochemical Assay Reagents P-glycoprotein Inflammation/Immunology
    Poloxamer 401 L121 is a block copolymer of polyethylene oxide and polypropylene oxide with an average molecular weight of 4400. Poloxamer has the ability to inhibit P-gp. Poloxamer 401 inhibits multiagent resistance and adjuvant activity. Poloxamer 401 can be used as a cosmetic ingredient. Poloxamer 401 can be used in nanoparticle engineering (lymphatic targeting particles) research .
    Poloxamer 401 (L121)
  • HY-P1380A

    Apoptosis Cancer
    Difopein TFA, a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interactions. Difopein TFA is not cell permeable. Difopein TFA leads to induction of apoptosis and enhances the ability of Cisplatin (HY-17394) to kill cells .
    Difopein TFA
  • HY-W008951

    EDTMP

    Radionuclide-Drug Conjugates (RDCs) Neurological Disease Cancer
    Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .
    Ethylenediaminetetra(methylenephosphonic acid)
  • HY-W013386
    LY83583
    1 Publications Verification

    Guanylate Cyclase Cardiovascular Disease Neurological Disease Cancer
    LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease .
    LY83583
  • HY-P1848
    Pep-1 (uncapped)
    2 Publications Verification

    Interleukin Related Cancer
    Pep-1 (uncapped) is a specific ligand of IL-13Ra2. Pep-1 (uncapped) exerts cell penetrating activity through receptor-mediated endocytosis, can cross the blood-tumor barrier (BTB) and target glioma cells. Pep-1 (uncapped) can enhance the uptake of nanoparticles by tumor cells and enhance the cell penetration ability of nanoparticles, and can be used to develop targeted drug delivery systems for glioma .
    Pep-1 (uncapped)
  • HY-P10732

    Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-cyclo(RGDfK)
  • HY-P10501A

    Antifolate Cancer
    FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7 TFA
  • HY-158072

    Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAM-NHS-ester is a bifunctional chelator and a macrocyclic DOTA derivative used for tumor pre-targeting. DOTAM-NHS-ester combines the efficient metal chelating ability of DOTAM macrocyclic ligands with the bioconjugation function of NHS ester active groups, and can be widely used in the biomedical field for metal labeling, molecular imaging and drug delivery development .
    DOTAM-NHS-ester
  • HY-132260

    IMGN529; Debio 1562

    Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis .
    Naratuximab emtansine
  • HY-W008003

    Cytochrome P450 Others
    2-Hydroxybenzimidazole is an inactive compound targeting CYP1A1 and is mainly used as a control compound in the structure-activity relationship study of benzimidazole derivatives. 2-Hydroxybenzimidazole does not have the ability to induce CYP1A1 expression like its thiol or amino substituted derivatives .
    2-Hydroxybenzimidazole
  • HY-W873634

    TRAP-Pr

    Radionuclide-Drug Conjugates (RDCs) Cancer
    TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
    TRAP
  • HY-157512

    Ligands for E3 Ligase Cancer
    SJF-0661 is a variant of the von Hippel-Lindau (VHL) protein ligand with no targeted degradation ability and can be used as a control reagent for the VHL ubiquitin ligase ligand. SJF-0661 is a variant obtained by inverting the stereocenter of the key hydroxyproline group in the VHL ligand .
    SJF-0661
  • HY-W011118

    Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA anhydride is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. DTPA anhydride can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DTPA anhydride
  • HY-178489

    Nectin-4 Cancer
    BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10 -7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .
    BGC1614
  • HY-164653

    Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTAEt
  • HY-164590

    Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    BCN-NODAGA
  • HY-P10730

    Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-Lanreotide
  • HY-164594

    Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA-GA
  • HY-P10501

    Antifolate Cancer
    FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7
  • HY-177921

    Liposome Others
    PL53 is a kind of cycloalkylamine lipid nanoparticles. PL53 exhibits outstanding transfection efficiency both in vitro and in vivo, especially showing strong protein expression ability and potential tissue targeting after intramuscular injection. PL53 can be used for the study of nucleic acid delivery .
    PL53
  • HY-177731

    Molecular Glues MicroRNA Cancer
    MG-Lin1 is a molecular glucose degrading agent that targets the Lin28 protein. MG-Lin1 can significantly reduce the mRNA levels of let-7 targeting oncogenes. MG-Lin1 can significantly inhibit the migration ability of cancer cells. MG-Lin1 has no obvious cytotoxicity. MG-Lin1 can be used for cancer research .
    MG-Lin1
  • HY-113011R

    Reference Standards Endogenous Metabolite Others
    Maltotriose (Standard) is the analytical standard of Maltotriose (HY-13011). This product is intended for research and analytical applications. Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
    Maltotriose (Standard)
  • HY-151207

    Apoptosis ADC Payload Cancer
    Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .
    Anticancer agent 81
  • HY-169208

    TAM Receptor Cancer
    MerTK-IN-1 (compund 31) is a MerTK inhibitor with in vivo target binding ability .
    MerTK-IN-1
  • HY-164589

    Radionuclide-Drug Conjugates (RDCs) Cancer
    NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NOPO
  • HY-164599

    Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA
  • HY-P10731

    Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-NAPamide
  • HY-164592

    Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA-tetra(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DTPA-tetra(tBu)ester
  • HY-W999782

    Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-DOTA-tris(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging .
    Propargyl-DOTA-tris(tBu)ester
  • HY-164603

    Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NOTA
  • HY-W999766

    Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging.
    Propargyl-NOTA(tBu)2
  • HY-164596

    Radionuclide-Drug Conjugates (RDCs) Cancer
    THP(Bz3)-Glu is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    THP(Bz3)-Glu
  • HY-164654

    Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-PEG10-azide
  • HY-W586475

    Radionuclide-Drug Conjugates (RDCs) Cancer
    Fluorescein-triazole-PEG5-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Fluorescein-triazole-PEG5-DOTA
  • HY-172283C

    Liposome Cancer
    DSPE-PEG3400-BR2 is a PEG compound which composed of DSPE and a BR2. BR2 is a targeting peptide composed of 17 amino acids with the sequence RAGLQFPVGRLLRRLLR. It has the ability to assist cells to penetrate the membrane and can specifically target certain cells or tissues .
    DSPE-PEG3400-BR2
  • HY-172283

    Liposome Cancer
    DSPE-PEG1000-BR2 is a PEG compound which composed of DSPE and a BR2. BR2 is a targeting peptide composed of 17 amino acids with the sequence RAGLQFPVGRLLRRLLR. It has the ability to assist cells to penetrate the membrane and can specifically target certain cells or tissues .
    DSPE-PEG1000-BR2
  • HY-172283B

    Liposome Cancer
    DSPE-PEG5000-BR2 is a PEG compound which composed of DSPE and a BR2. BR2 is a targeting peptide composed of 17 amino acids with the sequence RAGLQFPVGRLLRRLLR. It has the ability to assist cells to penetrate the membrane and can specifically target certain cells or tissues .
    DSPE-PEG5000-BR2
  • HY-164593

    Radionuclide-Drug Conjugates (RDCs) Cancer
    NH-CH2-CH2-DOTAM is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NH-CH2-CH2-DOTAM
  • HY-155546

    Bacterial Infection
    Antimicrobial agent-22 (THI 6c) is a multi-target broad-spectrum antibacterial agent. Antimicrobial agent-22 has low cytotoxicity, hemolytic property, rapid bactericidal ability and good anti-biofilm activity .
    Antimicrobial agent-22
  • HY-116264

    Ser/Thr Protease Cancer
    CatB-IN-1 is an enzyme inhibitor with significant inhibitory activity against tumor invasion. CatB-IN-1 may reduce the invasiveness of tumor cells by regulating intracellular protein metabolism. CatB-IN-1 demonstrates effective anti-invasive ability in cell models and can significantly reduce the invasive ability of MCF-10A neoT cells. The structure-activity relationship study of CatB-IN-1 shows that its design can target multiple functions of cat hepsin B .
    CatB-IN-1
  • HY-W814315

    CH5424802 analog; RO5424802 analog; RG7853 analog

    Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib analog (CH5424802 analog) is a selective ALK inhibitor with activity in blocking resistance gating mutations. The synthetic optimization of alectinib analog allows it to be combined with specific peptides to improve the ability to target cancer cells. Alectinib analog exhibits low micromolar IC50 values in antiproliferation and shows good cytotoxic effects. The inhibitory activity of alectinib analog is closely related to its stability and release of active ingredients. Alectinib analog demonstrated the ability to inhibit vascular septal length or width in an in vivo zebrafish model .
    Alectinib analog
  • HY-164656

    Drug-Linker Conjugates for ADC Cancer
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE
  • HY-164588

    Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-NODA-GA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: